Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Trial Profile

A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2019

At a glance

  • Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
  • Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Dec 2018 Results assessing safety and efficacy of Alisertib in combination with bortezomib and rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2018 Biomarkers information updated
    • 16 Feb 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top